Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
Key Points
Key points are not available for this paper at this time.
Abstract
ClinicalTrials.gov identifier: NCT02417064.
Like
Bookmark
Share
View Full Paper
Like
Bookmark
Share
View Full Paper
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) | Synapse